GlassScriptPhysician profile
John K Otero
NPI 1265522635
$6,473.58
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $773 · 2021: $1,392 · 2022: $2,210 · 2023: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $646.87 | 2019-2023 | Xtampza, Belbuca |
| Abbvie INC. | $627.29 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $486.71 | 2019-2022 | |
| Nevro Corp. | $486.48 | 2019-2023 | Senza |
| Medtronic, INC. | $470.41 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.08 | 2019-2022 | |
| Electronic Waveform Lab, INC. | $233.18 | 2020-2022 | |
| Abbott Laboratories | $232.57 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $228.62 | 2022 | |
| Allergan, INC. | $222.41 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $206.88 | 2019-2021 | |
| Boston Scientific Corporation | $203.26 | 2020-2023 | |
| Redhill Biopharma INC. | $200.74 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $165.60 | 2021 | |
| Stimwave Technologies Incorporated | $164.13 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $163.46 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $156.56 | 2019-2021 | |
| Medtronic USA, INC. | $154.51 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $143.72 | 2022-2023 | Quviviq |
| Relievant Medsystems, INC. | $133.11 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $109.50 | 2019-2020 | |
| Lilly USA, LLC | $107.84 | 2019-2023 | Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $91.18 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.03 | 2019-2020 | |
| Tersera Therapeutics LLC | $69.47 | 2019 | |
| Arbor Pharmaceuticals, INC. | $56.50 | 2019-2021 | |
| Amgen INC. | $52.09 | 2022 | |
| Kaleo, INC. | $41.83 | 2019 | |
| Assertio Therapeutics, INC. | $40.46 | 2019 | |
| Shionogi INC | $39.03 | 2019 | |
| Pfizer INC. | $29.60 | 2020-2021 | |
| Daiichi Sankyo INC. | $24.65 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $20.92 | 2023 | Exparel, Iovera, Zilretta |
| Mdd US Operations, LLC | $19.83 | 2019 | |
| Horizon Therapeutics Plc | $18.74 | 2022 | |
| Forte Bio-Pharma LLC | $17.40 | 2019 | |
| Flowonix Medical Incorporated | $16.39 | 2019 | |
| Fidia Pharma USA INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Otero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.